SYDNEY, AUSTRALIA: ZOONO Group Limited (ASX: ZNO), a global biotech company, has introduced the appointment of Mr. Barry Woolcott as Group Chief Executive Officer (CEO).
Following an extensive executive search, Mr. Woolcott joined Zoono in September 2021, initially as Global General Manager, with the intention that, at a mutually agreed date, he would assume the role of Chief Executive Officer.
Commenting on the appointment, Managing Director and main shareholder, Mr. Paul Hyslop, said “The Board is delighted to confirm Barry’s appointment as CEO.”
“Since becoming a member of the Company, Barry has been focussed on technique development and project delivery. He is uniquely positioned to perceive the challenges and alternatives that face Zoono. Barry has confirmed management capabilities and I look ahead to working with him to develop our Company.”
“Our priorities in selecting a brand new CEO were to identify somebody who could lead the Company through a transformational growth phase and information the Company’s focused global activities. Equally critical was a demonstrated ability to develop the Company’s capabilities and tradition to suit the evolving enterprise environment.”
Mr. Woolcott said he was excited to have the chance to lead Zoono. “Zoono is a nice firm with a fantastic product vary and an thrilling future. I look ahead to working with the administration team to transform the way we work as we glance to continually enhance and evolve.”
Prior to becoming a member of Zoono, Mr. Woolcott developed his administration capabilities through 7 years at Deloitte and, extra recently, thirteen years (the final eight as Group CEO) at Jacobsen Holdings, a privately owned group of New Zealand based companies.
Mr. Woolcott holds a Bachelor of Commerce with Honours from Queens University, Kingston, Ontario and an MBA from Auckland University.
ZOONO Group Limited is a global biotech firm that develops, manufactures, and distributes a suite of scientifically validated, long-lasting and environmentally pleasant antimicrobial solutions. ZOONO’s mission is to enhance well being and well-being through innovative, safe, non-toxic and sturdy germ protection.
ZOONO produces sprays, wipes and foams suited for pores and skin care, floor sanitisers, and mould remediation treatments. The merchandise are based on the ‘ZOONO molecule’, a distinctive antimicrobial molecule that bonds to any floor and kills pathogens together with bacteria, viruses, algae, fungi, and mould.
ZOONO’s merchandise have received quite a few regulatory approvals and ZOONO’s technology claims are supported by independent testing conducted in laboratories worldwide. ZOONO is headquartered in New Zealand and its merchandise can be found globally. www.ZOONO.com